This survey study aimed to (1) identify patient/family research priorities in pediatric-onset multiple sclerosis (POMS), and (2) delineate optimized methods for research study/clinical trials design, engagement, and implementation.
Methods:
Participants were as follows: (1) parents of a child (<18 years) with POMS enrolled in a national registry, (2) adolescents (13–17 years) with POMS in the registry, and (3) adults (18–40 years) with POMS receiving care at a registry affiliated clinic. Of 293 eligible participants, 192 completed surveys.
Results:
Experiences with health care and medications were generally positive but there remain areas of priority improvement. Incentives to participate in clinical trials included medications previously tested and in pill form, bloodwork/study visits required ⩾ every 3 months, cognitive testing ⩽1 hour, compensation for travel and time, ability to continue current multiple sclerosis (MS) medication, option to take study medication if on placebo, and individualized study feedback. Priorities for clinical research were (1) psychosocial impact, (2) cognitive/academic impact, (3) environmental risk, and (4) nutrition.
Conclusions:
Results highlighted the importance of a holistic approach to study design and a focus on the impact of disease on daily life to best engage patients and families in POMS clinical trials and research.
AlroughaniRBoykoA. Pediatric multiple sclerosis: A review. BMC Neurol2018; 18(1): 27.
2.
YanKBalijepalliCDesaiK, et al. Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis. Mult Scler Relat Disord2020; 44: 102260.
3.
PalisanoRJ. Bringing the family’s voice to research. Phys Occup Ther Pediatr2016; 36(3): 229–231.
4.
NeelDVShulmanDSDuBoisSG. Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer2019; 112: 49–56.
5.
DySMJanssenEMFerrisA, et al. Live, learn, pass it on: A patient advocacy engagement project on the lived experience of lung cancer survivors. J Patient Exp2017; 4(4): 162–168.
6.
AllshouseC. The importance of the family voice in quality measure development for children’s health care. Acad Pediatr2014; 14(5 Suppl.): S8–S9.
KryskoKMGravesJRenselM, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology2018; 91(19): e1778–e1787.
12.
ChitnisT. Disease-modifying therapy of pediatric multiple sclerosis. Neurotherapeutics2013; 10(1): 89–96.
13.
RenselM. Long-term treatment strategies of pediatric multiple sclerosis, including the use of disease modifying therapies. Children2019; 6(6): 73.
14.
BaronciniDSimoneMIaffaldanoP, et al. Risk of persistent disability in patients with pediatric-onset multiple sclerosis. JAMA Neurol2021; 78(6): 726–735.
15.
DuignanSBrownleeWWassmerE, et al. Paediatric multiple sclerosis: A new era in diagnosis and treatment. Dev Med Child Neurol2019; 61(9): 1039–1049.
16.
BelmanALKruppLBOlsenCS, et al. Characteristics of children and adolescents with multiple sclerosis. Pediatrics2016; 138(1): e20160120.
17.
GhezziA. Clinical characteristics of multiple sclerosis with early onset. Neurol Sci2004; 25Suppl 4: S336–S339.
18.
MacAllisterWSBoydJRHollandNJ, et al. The psychosocial consequences of pediatric multiple sclerosis. Neurology2007; 68(16 suppl. 2): S66–S69.
19.
GormanMPHealyBCPolgar-TurcsanyiM, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol2009; 66(1): 54–59.
20.
BaruchNFO’DonnellEHGlanzBI, et al. Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. Mult Scler2016; 22(3): 354–361.
21.
JulianLSerafinDCharvetL, et al. Cognitive impairment occurs in children and adolescents with multiple sclerosis: Results from a United States network. J Child Neurol2013; 28(1): 102–107.
22.
CharvetLEO’DonnellEHBelmanAL, et al. Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: Report from the US Pediatric Multiple Sclerosis Network. Mult Scler2014; 20(11): 1502–1510.
23.
VargasWGlendinningMStreetH, et al. Academic underachievement is common in pediatric-onset multiple sclerosis (P4-4.006). Neurology2022; 98(18 Suppl.): 33–80.
24.
Toussaint-DuysterLCWongYYMVan der Cammen-van ZijpMH, et al. Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis. Mult Scler2018; 24(7): 982–990.
25.
O’MahonyJMarrieRALaporteA, et al. Pediatric-onset multiple sclerosis is associated with reduced parental health–related quality of life and family functioning. Mult Scler2019; 25(12): 1661–1672.
26.
OwNKarpAOgeilJ, et al. Quality of life in pediatric-onset multiple sclerosis: Different disease course, different impact, different measurement approach needed. Mult Scler Relat Disord2022; 63: 103820.
27.
SobejanoIStoneySKunzelmanE, et al. Rates of depression and suicidality in pediatric-onset multiple sclerosis: A pilot study (P12-9.003). Neurology2023; 100(17 Suppl.): 24968.
28.
RowbothamNJSmithSLeightonPA, et al. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax2018; 73(4): 388–390.
29.
ByerLKlineCMuellerS. Clinical trials in pediatric neuro-oncology: What is missing and how we can improve. CNS Oncol2016; 5(4): 233–239.
30.
BrunnerHIRiderLGKingsburyDJ, et al. Pediatric rheumatology collaborative study Group—over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatr Rheumatol2018; 16(1): 45.
31.
MandelLAO’DonnellECanenguezK, et al. Family perspectives on clinical research for pediatric multiple sclerosis: Enhancing equity. J Patient Exp2021; 8: 23743735211039319.
32.
RenouxCVukusicSMikaeloffY, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med2007; 356(25): 2603–2613.
33.
HardingKELiangKCossburnMD, et al. Long-term outcome of paediatric-onset multiple sclerosis: A population-based study. J Neurol Neurosurg Psychiatry2013; 84(2): 141–147.
34.
PortaccioEBellinviaARazzoliniL, et al. Long-term cognitive outcomes and socioprofessional attainment in people with multiple sclerosis with childhood onset. Neurology2022; 98(16): e1626–e1636.
35.
AllenTRedaSMartinS, et al. The needs of adolescents and young adults with chronic illness: Results of a quality improvement survey. Children2022; 9(4): 500.
